Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir

被引：21

作者：

Lalezari, J ^{[1
]}

机构：

[1] Univ Calif San Francisco, Mt Zion Hosp, NV15107 Study Grp, San Francisco, CA 94143 USA

来源：

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1998年 / 19卷 / 02期

关键词：

D O I：

10.1097/00042560-199810010-00015

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

收藏

页码：195 / 197

页数：3

相关论文

共 6 条

[1] Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
Collier, AC
Coombs, RW
Schoenfeld, DA
Bassett, RL
Timpone, J
Baruch, A
Jones, M
Facey, K
Whitacre, C
McAuliffe, VJ
Friedman, HM
Merigan, TC
Reichman, RC
Hooper, C
Corey, L
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) : 1011 - 1017
[2] CONWAY B, 1997, 37 INT C ANT AG CHEM
[3] ANTIVIRAL PROPERTIES OF RO 31-8959, AN INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) PROTEINASE
CRAIG, JC
DUNCAN, IB
HOCKLEY, D
GRIEF, C
ROBERTS, NA
MILLS, JS
[J]. ANTIVIRAL RESEARCH, 1991, 16 (04) : 295 - 305
[4] HAUBRICH R, 1996, AIDS S2, V10
[5] The effect of high-dose saquinavir on viral load and CD4(+) T-cell counts in HIV-infected patients
Schapiro, JM
Winters, MA
Stewart, F
Efron, B
Norris, J
Kozal, MJ
Merigan, TC
[J]. ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) : 1039 - 1050
[6] STELLBRINK HJ, 1997, 6 EUR C CLIN ASP TRE